1h Free Analyst Time
The binge-eating disorder treatment market is forecasted to grow by USD 578.04 mn during 2022-2027, accelerating at a CAGR of 7.26% during the forecast period. The report on the binge-eating disorder treatment market provides a holistic analysis, market size, and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of binge-eating disorder, the growing obese population, and rising government initiatives.
The binge-eating disorder treatment market is segmented as below:
By Distribution Channel
- Offline
- Online
By Type
- Antidepressants
- Anticonvulsants
- Stimulants and others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the binge-eating disorder treatment market covers the following areas:
- Binge-eating disorder treatment market sizing
- Binge-eating disorder treatment market forecast
- Binge-eating disorder treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Exhibits:
Executive Summary
The publisher recognizes the following companies as the key players in the global binge-eating disorder treatment market: Alvogen Iceland ehf, Bausch Health Co. Inc., Chronos Therapeutics Ltd., Currax Pharmaceuticals LLC, Eli Lilly and Co., Johnson and Johnson Services Inc., Lupin Ltd., Omeros Corp., Pyramid Healthcare Inc., Rosewood Centers for Eating disorders, Sumitomo Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Timberline Knolls Residential Treatment Center, Tonix Pharmaceuticals Holding Corp., Tryp Therapeutics Inc., Viatris Inc., VIVUS LLC, and Walden Behavioral Care.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is development and approval of new drugs.'
According to the report, one of the major drivers for this market is the increasing prevalence of binge-eating disorder.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alvogen Iceland ehf
- Bausch Health Co. Inc.
- Chronos Therapeutics Ltd.
- Currax Pharmaceuticals LLC
- Eli Lilly and Co.
- Johnson and Johnson Services Inc.
- Lupin Ltd.
- Omeros Corp.
- Pyramid Healthcare Inc.
- Rosewood Centers for Eating disorders
- Sumitomo Pharma Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Timberline Knolls Residential Treatment Center
- Tonix Pharmaceuticals Holding Corp.
- Tryp Therapeutics Inc.
- Viatris Inc.
- VIVUS LLC
- Walden Behavioral Care
